drugset
drugset / Trial / NCT05471531

Study on Combined Vaccination With Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine

NCT05471531 ↗

Phase 4 Completed 3000 enrolled Sinovac Biotech Co., Ltd
RandomizedParallel-groupOpen-labelPrevention

Summary

This study is an open-label,single center phase Ⅳ clinical trial of combined immunization with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine.The purpose of this study is to evaluate the safety and immunogenicity of combined immunization with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in the elderly aged 60 years and above.

Timeline

Start
2021-11-13
Primary completion
2022-03-10
Completion
2022-07-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Pneumovax 23 Vaccine — Intramuscular
Subject Quadrivalent influenza vaccine Vaccine — Intramuscular

Indications

No indication recorded.